Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2586116 nasal spray crossover study in moderate to severe obstructive sleep apnea
2020-000520-19Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BAY2586116 in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Bayer. Primary endpoint: Responder rate based on apnea-hypopnea index reduction. Started Nov 2020; status: completed.
02
Drugs
BAY2586116
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2020-000520-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000520-19.